Evidence map›Paper›PMID 37967247›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2024

Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.

Katrina B Dietsche, Sheela N Magge, Sydney A Dixon, Faith S Davis, Andrea Krenek, Aruba Chowdhury, Lilian Mabundo, Michael Stagliano, Amber B Courville, Shanna Yang and 17 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 1 country.

Katrina B DietscheNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Sheela N MaggeDivision of Pediatric Endocrinology and Diabetes, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-0949-4399
Sydney A DixonNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Faith S DavisNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Andrea KrenekNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Aruba ChowdhuryNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Lilian MabundoNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Michael StaglianoNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Amber B CourvilleNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Shanna YangClinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Sara TurnerClinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Hongyi CaiNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Kannan KasturiDivision of Pediatric Endocrinology, Essentia Health, Duluth, MN 55805, USA.
Arthur S ShermanNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Joon HaDepartment of Mathematics, Howard University, Washington, DC 20059, USA.
Eileen ShouppeNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Mary WalterNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Peter J WalterNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-8571-398X
Kong Y ChenNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0306-1904
Robert J BrychtaNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.
Cody PeerClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Yi ZengClinical Pharmacology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
William FiggClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Fran CogenDivision of Endocrinology and Diabetes, Children's National Hospital, Washington, DC 20010, USA.
D Elizabeth EstradaDivision of Endocrinology and Diabetes, Children's National Hospital, Washington, DC 20010, USA.
Shaji ChackoDepartment of Pediatrics, Children's Nutrition Research Center and Division of Pediatric Endocrinology and Metabolism, U.S. Department of Agriculture/Agricultural Research Service, Baylor College of Medicine, Houston, TX 77030, USA.
Stephanie T ChungNational Institute of Diabetes, Digestive and Kidney Diseases/National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6989-0417
National Institutes of Health · USNational Institutes of Health Clinical Center · USChildren's National · USAgricultural Research Service · USEssentia Health · USHoward University · USJohns Hopkins University · US

Funding

Clinical Mass Spectrometry CoreZICDK075039 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$3.3M
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · DIVISION OF CLINICAL SCIENCES - NCI · 2025 to 2025
$1.8M
Human Energy and Body Weight Regulation CoreZICDK071013 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$1.8M
Therapeutic targets in African-American youth with type 2 diabetesZIADK075133 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$279k
Bench-to-Bedside and Back (381469)Intramural Program of the National Institute of Diabetes and Digestive and Kidney DiseasesNational Institute of Minority Health and Health DisparitiesNational Institutes of Health Clinical Center
6 · The paper itself

Abstract

objectiveElevated rates of gluconeogenesis are an early pathogenic feature of youth-onset type 2 diabetes (Y-T2D), but targeted first-line therapies are suboptimal, especially in African American (AA) youth. We evaluated glucose-lowering mechanisms of metformin and liraglutide by measuring rates of gluconeogenesis and β-cell function after therapy in AA Y-T2D.

methodsIn this parallel randomized clinical trial, 22 youth with Y-T2D-age 15.3 ± 2.1 years (mean ± SD), 68% female, body mass index (BMI) 40.1 ± 7.9 kg/m2, duration of diagnosis 1.8 ± 1.3 years-were randomized to metformin alone (Met) or metformin + liraglutide (Lira) (Met + Lira) and evaluated before and after 12 weeks. Stable isotope tracers were used to measure gluconeogenesis [2H2O] and glucose production [6,6-2H2]glucose after an overnight fast and during a continuous meal. β-cell function (sigma) and whole-body insulin sensitivity (mSI) were assessed during a frequently sampled 2-hour oral glucose tolerance test.

resultsAt baseline, gluconeogenesis, glucose production, and fasting and 2-hour glucose were comparable in both groups, though Met + Lira had higher hemoglobin A1C. Met + Lira had a greater decrease from baseline in fasting glucose (-2.0 ± 1.3 vs -0.6 ± 0.9 mmol/L, P = .008) and a greater increase in sigma (0.72 ± 0.68 vs -0.05 ± 0.71, P = .03). The change in fractional gluconeogenesis was similar between groups (Met + Lira: -0.36 ± 9.4 vs Met: 0.04 ± 12.3%, P = .9), and there were no changes in prandial gluconeogenesis or mSI. Increased glucose clearance in both groups was related to sigma (r = 0.63, P = .003) but not gluconeogenesis or mSI.

conclusionAmong Y-T2D, metformin with or without liraglutide improved glycemia but did not suppress high rates of gluconeogenesis. Novel therapies that will enhance β-cell function and target the elevated rates of gluconeogenesis in Y-T2D are needed.

Indexed as

Diabetes Mellitus, Type 2MetforminAdolescentBlood GlucoseFemaleGluconeogenesisGlucoseHumansHypoglycemic AgentsLiraglutideMaleBlood GlucoseGlucoseHypoglycemic AgentsLiraglutideMetforminGLP-1 receptor agonistgluconeogenesisglucose productionmetforminminority healthpediatrictype 2 diabetes

Identifiers

PMID37967247
PMCPMC11031226
OpenAlexW4388737132

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.